basiliximab

IV (Adults and Children ≥35 kg): 20 mg given 2 hr before transplantation; repeated 4 days after transplantation. Second dose should be withheld if complication or graft loss occurs.
IV (Children <35 kg): 10 mg given 2 hr before transplantation; repeated 4 days after transplantation. Second dose should be withheld if complication or graft loss occurs.

US Brand Names ⬆ ⬇

Action ⬆ ⬇

Binds to and blocks specific interleukin-2 (IL-2) receptor sites on activated T lymphocytes.

Therapeutic effects:

Classifications ⬆ ⬇

Therapeutic Classification: Immunosuppressant agents

Pharmacologic Classification: monoclonal antibodies

Pharmacokinetics ⬆ ⬇

Absorption: IV administration results in complete bioavailability.

Distribution: Moderately distributed to tissues.

Metabolism/Excretion: Unknown.

Half-Life: 7.2 days.

Time/Action Profile ⬆ ⬇

(effect on immune function)

ROUTE	ONSET	PEAK	DURATION
IV	2 hr	unknown	36 days

Patient/Family Teaching ⬆ ⬇

Explain purpose of medication to patient. Explain that patient will need to resume lifelong therapy with other immunosuppressive drugs after completion of basiliximab course.
May cause dizziness. Caution patient to avoid driving or other activities requiring alertness until response is known.
Instruct patient to continue to avoid crowds and persons with known infections, because basiliximab also suppresses the immune system.
Rep: Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Pronunciation ⬆ ⬇

Code ⬆

NDC Code

0078- Novartis Pharmaceuticals Corporation
- 0078-0331- Simulect
  - 0078-0331-84- 1 VIAL, SINGLE-USE in 1 CARTON (0078-0331-84) > 5 mL in 1 VIAL, SINGLE-USE

0078- Novartis Pharmaceuticals Corporation
- 0078-0393- Simulect
  - 0078-0393-61- 1 VIAL, SINGLE-USE in 1 CARTON (0078-0393-61) > 2.5 mL in 1 VIAL, SINGLE-USE